@pedrofsrocha

Medical Oncologist at Vall d’Hebron University Hospital, Barcelona, Spain | IASLC SCLC Committee member | Former MDAnderson Cancer Center Postdoctoral Fellow

 Barcelona, Spain
Joined November 2014
  • Tweets310
  • Following672
  • Followers573
14Media
International Association for the Study of Lung Cancer - Dr. Pedro Rocha on DeLLphi-308 Study at #WCLC26 @IASLC @pedrofsrocha
1
2
4
226
Pedro Rocha retweeted
IASLC
@IASLCOct 4
🫁 #WCLC26 recap: Subcutaneous tarlatamab shows promising antitumor activity, safety profile in ES-SCLC. 🔗 Read the presentation highlights in ILCN: bit.ly/4hots0D #LCSM

Subcutaneous Tarlatamab Shows Promising Antitumor Activity, Safety Profile in ES-SCLC - ILCN.org...

Dr. Pedro Rocha, MD, PhD, said data from the DeLLphi-308 study indicate that subcutaneous tarlatamab can achieve serum exposures comparable to intravenous administration in a heavily pretreated...

ilcn.org
1
6
25
1,715
#DeLLphi308- was a small Phase 1B study but encouraging safety profile for subcutaneous #tarlatamab at 15mg dose Q2 weeks for ES-SCLC reducing CRS/ICANS rate allowing for ⬇️ 1-2 hr observation post dosing— moving us closer to being able to give this treatment more comfortably in clinic to a wider patient population.
The ASCO Post@ASCOPostSep 16
🫁 In DeLLphi-308, subcutaneous tarlatamab showed a favorable safety profile and preliminary antitumor activity in previously treated ES-SCLC. ➡️ Objective response rates were 20% at 10 mg and 30% at 15 mg. 🗣️ Presented by @pedrofsrocha at #WCLC26 🔗 ascopost.com/news/september-…
3
7
1,204
#WCLC26 | DeLLphi-308 💉 Ph1b: subcutaneous tarlatamab in previously treated ES-SCLC (N=60); 15 mg SC Q2W selected for expansion. 📈 15 mg SC achieved exposure comparable to 10 mg IV Q2W 💡 CRS: 38%, all G1–2 • G≥3 CRS: 0% • ICANS: 0% ↪️ historical IV CRS: 56% 🎯 Antitumor activity maintained: • ORR: 30% • DCR: 55% • median DoR: NR • mPFS: 3.7 mo • mOS: 11.7 mo 🛡️ Overall ≧Gr3 TRAEs: 13% Treatment discontinuation: 2%; no fatal TRAEs
2
6
30
3,103
Pedro Rocha retweeted
Amgen 🧪🔬🧬
@AmgenSep 8
📢 #SCLC news: Amgen announced that a Phase 3 study evaluating its DLL3-targeting therapy as part of first-line maintenance treatment for patients with extensive-stage small cell lung cancer met its primary endpoint ➡️ Learn more: amgen.ly/4ihHq5p $AMGN
1
16
8
36
13,299
🆙#WCLC26 #LCSM Oral Session 🔥DeLLphi-309: Tarlatamab Extended-Interval Dosing Regimens in Patients With SCLC: The Randomized Phase 2 Study 🎙️Dr. Jonathan W. Goldman 🔢OA05.01 ☑️NCT06745323 🔗 cattendee.abstractsonline.co… @OncoAlert @Larvol @IASLC
7
1
16
7,748
Pedro Rocha retweeted
ASEICA@ASEICAnewsApr 21
‼️Mañana, 22 de abril No te pierdas el 3er webinar ASEICA y @_SEOM ⬇️⬇️
ASEICA@ASEICAnewsApr 14
📍3er Webinar ASEICA y @_SEOM para acercar la investigación traslacional a residentes y adjuntos jóvenes de Oncología Médica. 📢Microambiente tumoral I-Genómica Con: ✅Domingo A. Sánchez Martínez. (HU Virgen de la Arrixaca) ✅Jon Zugazagoitia. (HU 12 Octubre) 📅22 ABR ⏰16:30h
4
8
700
Pedro Rocha retweeted
Cancer Discovery@CD_AACRApr 19
Online now for #AACR26 by the @AACR Lung Cancer Task Force - A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention and Interception aacrjournals.org/cancerdisco… @CharlesSwanton @LabWinslow
18
5
36
9,184
💯SEOM y ASEICA unen clínica e investigación en su primer webinar sobre investigación traslacional. Una cita clave para entender la ciencia que impulsa nuestra práctica médica. 🗓️ Miércoles, 25 de febrero | 16:30h ➡️ Inscríbete gratis aquí: seom.org/otros-servicios/not…
ASEICA@ASEICAnewsJan 26
🤝ASEICA y el @_SEOM lanzan un programa de webinars de cinco sesiones para acercar la investigación traslacional a médicos residentes y adjuntos.  🔜La primera sesión será el miércoles 25 de febrero a las 16.30 horas.  👉Inscríbete al programa aquí seom.org/otros-servicios/not…
3
3
598
Outcomes of concurrent radiotherapy with #tarlatamab in extensive-stage SCLC from the DLL3 PanTUMOR database suggest this approach is feasible and safe, with no delayed CRS or ICANS observed. Read more: bit.ly/3ZmDiq8
2
12
26
2,603
‼️🔔 Para oncólogos médicos interesados en formación en investigación traslacional @_SEOM @ASEICAnews ⬇️⬇️⬇️
Yago Garitaonaindía
@YGaritaonaindiaJan 19
🚨📣En 2026 ponemos en marcha, desde la Sección +MIR de @_SEOM y junto con @ASEICAnews, un programa de webinars en investigación traslacional. La idea es sencilla: ayudar a entender mejor de dónde salen los datos que usamos a diario y cómo interpretarlos (1/2)
6
10
2,045
Pedro Rocha retweeted
Raffaele Califano@calirafJan 18
ow.ly/6GHk50XVhxw Deadline for application is 21 jan! @myESMO @TheChristieNHS @BTOGORG @ALKPositiveinc
4
7
661
Pedro Rocha retweeted
Justin Gainor@JustinGainorJan 17
Collaborative study between MGB Thoracic and Haber, Mishra, Toner and Maheswaran labs shows DLL3 CTCs are highly predictive for outcomes with tarlatamab in SCLC. Also provide insights into CRS and mechanisms of resistance. aacrjournals.org/cancerdisco…
2
21
1
83
6,745
🩺 @EnriquetaFelip, candidata a Top 100 Mujeres Líderes en España en la categoría Académicas e Investigadoras. 🗳️ Vota aquí 👉 linke.to/EnriquetaFelip2025 📅 Hasta el 28/12/2025 #Top100MujeresLíderes
2
3
338
Pedro Rocha retweeted
IASLC
@IASLC18 Dec 2025
🎉 VIKTOR is here! The Virtual International Knowledgebase for Thoracic Oncology Research brings global preclinical model data into one searchable platform to help researchers compare models and accelerate discovery. IASLC members: access now! iaslc.org/viktor
1
6
18
1,396
Pedro Rocha retweeted
Oriol Pich@oriol_pich17 Dec 2025
Happy to share our latest study @Nature , where we evaluate somatic evolution and the effect of treatment in normal tissue using duplex sequencing 1/n nature.com/articles/s41586-0…

Somatic evolution following cancer treatment in normal tissue

Nature - High-depth sequencing of non-cancerous tissue from patients with metastatic cancer reveals single-base mutational signatures of alcohol, smoking and cancer treatments, and reveals how...

nature.com
3
43
2
157
28,424
An Analysis benchmarks 50 state-of-the-art TCR-epitope binding prediction methods. nature.com/articles/s41592-0…

Assessment of computational methods in predicting TCR–epitope binding recognition

Nature Methods - This Analysis benchmarks 50 state-of-the-art TCR–epitope binding prediction methods and evaluates key factors that influence predictive performance.

nature.com
28
1
113
12,669
Proud to share our SAKK 15/19 phase II trial, the first Swiss multicenter study testing thoracic radiotherapy conomitantly with IO maintenance after chemo-IO in ES-SCLC. ➡️ TRT + durvalumab was safe, improved local control (only 27% thoracic relapse), though the primary endpoint was not met. ➡️ Median OS reached 15 months, despite 30% pts with brain mets. A key step toward clarifying TRT’s role in the IO era. Phase III trials like RAPTOR will tell us more. ejcancer.com/article/S0959-8… @alessandracuriomi #lcsm #SCLC #immunotherapy #radiotherapy @SAKK_ch

Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus...

Small cell lung cancer (SCLC) is an aggressive tumour type accounting for 10–15 % of lung cancers. The role of thoracic radiotherapy (TRT) in extensive stage SCLC (ES_SCLC) in the era of checkpoint...

ejcancer.com
5
15
48
3,706
Pedro Rocha retweeted
EORTC@EORTC1 Dec 2025
📢 Save the date! EORTC Lung Cancer Group Webinar on Clinical Trials in Stage III NSCLC. 📅 17 Dec | 🕕 18:00 CET Learn from oncology, radiotherapy & surgery experts. Free and open to all! 🔗 Register here: eortc.wufoo.com/forms/z1hdya… #EORTClung #NSCLC #ClinicalTrials #Oncology
7
11
1,068
New in #ES_SCLC JCO, @charlesrudin et al. ascopubs.org/doi/10.1200/JCO…: B7-H3 ADC ifinatamab deruxtecan (I-DXd) in pretreated pts. At 12 mg/kg Q3W (n=137): 🔹 ORR 48% (56% in 2L) 🔹 DOR 5.3 mo 🔹 PFS 4.9 mo 🔹 OS 10.3 mo Incl. many with brain mets & CTFI <90d. Promising signal in a very tough space.

Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of...

PURPOSETreatment options for patients with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) are limited. This phase II trial evaluated the efficacy and safety of ifinatamab...

ascopubs.org
3
12
32
4,216
Load more